Sex, male, n (%) | 207 (57.8) |
Age, mean (SD) y | 66.1 (14.3) |
Age group, n (%) | |
< 85 y | 332 (92.7) |
≥ 85 y | 26 (7.3) |
Primary site, n(%) | |
Tongue | 177 (49.4) |
Lower gingiva | 71 (19.8) |
Upper gingiva | 47 (13.1) |
Buccal mucosa | 31 (8.7) |
Oral floor | 22 (6.1) |
Lip | 4 (1.1) |
Palate | 6 (1.7) |
T stage, n(%) | |
Tis | 15 (4.2) |
T1 | 49 (13.7) |
T2 | 88 (24.6) |
T3 | 75 (20.9) |
T4a | 123 (34.4) |
T4b | 8 (2.2) |
N stage, n(%) | |
N0 | 257 (71.8) |
N1 | 31 (8.7) |
N2b | 33 (9.2) |
N2c | 11 (3.1) |
N3b | 26 (7.3) |
M stage, n(%) | |
M0 | 357 (99.7) |
M1 | 1 (0.3) |
Stage, n(%) | |
Stage 0 | 21 (5.9) |
Stage 1 | 46 (12.1) |
Stage 2 | 74 (20.7) |
Stage 3 | 69 (19.3) |
Stage 4a | 116 (32.4) |
Stage 4b | 31 (8.7) |
Stage 4c | 6 (0.3) |
Treatment, n(%) | |
Operative treatment | 314 (87.7) |
Surgery only | 225 (71.7) |
Surgery and postoperative chemotherapy | 52 (16.6) |
Surgery and postoperative radiation | 6 (1.9) |
Surgery and postoperative chemoradiation | 31 (9.9) |
Non-operative treatment | 44 (12.3) |
Chemotherapy | 3 (6.8) |
Radiation | 13 (29.5) |
Chemoradiation | 28 (63.6) |